Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2005-7-18
pubmed:abstractText
Dihydropyrimidine dehydrogenase (DPD), known as a rate-limiting metabolic enzyme in the catabolism of 5-fluorouracil (5-FU), degrades more than about 80% of the administered 5-FU in human liver. Since it was reported that the anticancer effects of 5-FU were observed in cancer patients with lower DPD activities, many attempts have been conducted to anticipate the expected anticancer effects of 5-FU based on expression of intracanceral DPD. It have been reported that 39 different mutations and polymorphisms in the coding regions of DPD genes have been identified; however, there is no report on polymorphisms in the 5'-flanking region of DPD genes. We investigated polymorphisms in the 5'-flanking regions (3,058 bp), which are considered to control expression of DPD genes, in genomic DNA extracted from 37 kinds of human cancer cells. As the results, out of 37 cancer cells subjected to analysis, DLD- 7 cells had C insertion and 7 strains G deletion, which were hetelozygote. No significant relationship was identified between the DPD activity and the expression levels of DPD mRNA in examined 10 kinds of human cancer cells. However, in DLD-1 cells, which have C-insertion polymorphism in 5'-flanking region of DPD gene, the DPD activity was below detection limit (< or = 0.5 pmol/min/mg protein). Furthermore, 50% of cytosine residue on the CpG site generated by the C insertion was methylated at the 5 position. In this study, we have identified novel polymorphism possibly related the cytotoxicity of 5-FU in the 5'-flanking region of DPD gene. It is suggested that newly identified polymorphism of DPD gene might affect transcription of DPD, thereby providing influence on the clinical outcome of cancer patients treated with 5-FU.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1525-7770
pubmed:author
pubmed:issnType
Print
pubmed:volume
24
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
233-42
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:16021908-Antimetabolites, Antineoplastic, pubmed-meshheading:16021908-Cell Line, Tumor, pubmed-meshheading:16021908-CpG Islands, pubmed-meshheading:16021908-Cytosine, pubmed-meshheading:16021908-DNA Methylation, pubmed-meshheading:16021908-DNA Primers, pubmed-meshheading:16021908-Dihydrouracil Dehydrogenase (NADP), pubmed-meshheading:16021908-Down-Regulation, pubmed-meshheading:16021908-Fluorouracil, pubmed-meshheading:16021908-Gene Expression Regulation, Neoplastic, pubmed-meshheading:16021908-Heterozygote, pubmed-meshheading:16021908-Humans, pubmed-meshheading:16021908-Liver, pubmed-meshheading:16021908-Models, Genetic, pubmed-meshheading:16021908-Mutation, pubmed-meshheading:16021908-Oligonucleotide Array Sequence Analysis, pubmed-meshheading:16021908-Polymerase Chain Reaction, pubmed-meshheading:16021908-Polymorphism, Genetic, pubmed-meshheading:16021908-Polymorphism, Restriction Fragment Length, pubmed-meshheading:16021908-Sequence Analysis, DNA, pubmed-meshheading:16021908-Sulfites, pubmed-meshheading:16021908-Transcription, Genetic
pubmed:year
2005
pubmed:articleTitle
Sequence analysis of the 5'-flanking regions of human dihydropyrimidine dehydrogenase gene: identification of a new polymorphism related with effects of 5-fluorouracil.
pubmed:affiliation
Faculty of Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-naka, Okayama-shi, Okayama 700-8530, Japan. wataya@cc.okayamau.ac.jp
pubmed:publicationType
Journal Article